Stock listing
NASDAQ:CCCC C4 Therapeutics, Inc. Stock
Home listing (NASDAQ) of C4 Therapeutics, Inc.
Follow C4 Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CCCC
$2.48 USD +0.00 (+0.2%)
Close on Nov 20, 2026
- Day range
- $2.32 – $2.55 USDNov 20, 2026
- Volume
- 3.63M sharesNov 20, 2026
- Market cap
- $325.7M USDAt the close on Nov 20, 2026 · price × 131.3M shares outstanding
- 52-week range
- $1.69 – $5.17 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.92M USDMedian day 2.32M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CCCC · Home | $2.48 USD | +0.005 (+0.2%) | 3,628,833 | $2.39 | $2.545 | $2.321 | $2.475 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CCCC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.48 | +0.005 | +0.2% | $2.39 | $2.545 | $2.321 | 3,628,833 | |
| $2.475 | -0.055 | -2.2% | $2.51 | $2.605 | $2.47 | 2,749,817 | |
| $2.53 | -0.12 | -4.5% | $2.66 | $2.66 | $2.38 | 2,839,069 | |
| $2.65 | -0.11 | -4.0% | $2.72 | $2.76 | $2.59 | 3,105,695 | |
| $2.76 | -0.01 | -0.4% | $2.76 | $2.85 | $2.671 | 2,543,577 | |
| $2.77 | -0.12 | -4.2% | $2.86 | $2.86 | $2.64 | 4,965,262 | |
| $2.89 | -0.11 | -3.7% | $3.04 | $3.05 | $2.86 | 2,132,635 | |
| $3.00 | -0.15 | -4.8% | $3.11 | $3.155 | $2.93 | 1,453,554 | |
| $3.15 | +0.05 | +1.6% | $3.13 | $3.225 | $3.04 | 2,388,734 | |
| $3.10 | +0.15 | +5.1% | $2.96 | $3.20 | $2.951 | 2,965,794 | |
| $2.95 | -0.17 | -5.4% | $3.08 | $3.22 | $2.905 | 3,683,946 | |
| $3.12 | -0.09 | -2.8% | $3.36 | $3.385 | $3.02 | 1,971,831 | |
| $3.21 | 0.00 | 0.0% | $3.27 | $3.42 | $3.17 | 1,584,944 | |
| $3.21 | -0.16 | -4.7% | $3.36 | $3.41 | $3.16 | 2,861,726 | |
| $3.37 | +0.07 | +2.1% | $3.23 | $3.38 | $3.21 | 2,354,062 | |
| $3.30 | -0.095 | -2.8% | $3.41 | $3.44 | $3.20 | 2,714,989 | |
| $3.395 | +0.185 | +5.8% | $3.25 | $3.525 | $3.23 | 4,108,477 | |
| $3.21 | +0.23 | +7.7% | $2.99 | $3.24 | $2.95 | 4,118,932 | |
| $2.98 | -0.08 | -2.6% | $3.07 | $3.07 | $2.94 | 3,179,037 | |
| $3.06 | -0.12 | -3.8% | $3.16 | $3.17 | $3.02 | 4,741,850 | |
| $3.18 | +0.01 | +0.3% | $3.13 | $3.25 | $3.12 | 1,692,802 | |
| $3.17 | +0.01 | +0.3% | $3.15 | $3.22 | $3.10 | 2,189,796 | |
| $3.16 | +0.27 | +9.3% | $2.86 | $3.20 | $2.855 | 3,689,396 | |
| $2.89 | +0.125 | +4.5% | $2.80 | $2.94 | $2.80 | 3,113,184 | |
| $2.765 | -0.015 | -0.5% | $2.78 | $2.81 | $2.695 | 2,359,300 | |
| $2.78 | +0.17 | +6.5% | $2.64 | $2.846 | $2.60 | 3,274,900 | |
| $2.61 | -0.17 | -6.1% | $2.72 | $2.795 | $2.59 | 3,094,000 | |
| $2.78 | -0.28 | -9.2% | $3.04 | $3.06 | $2.75 | 3,821,400 | |
| $3.06 | -0.10 | -3.2% | $3.16 | $3.30 | $3.05 | 1,500,400 | |
| $3.16 | +0.31 | +10.9% | $3.00 | $3.19 | $2.95 | 2,506,100 | |
| $2.85 | +0.03 | +1.1% | $2.80 | $2.88 | $2.721 | 2,827,700 | |
| $2.82 | -0.06 | -2.1% | $2.85 | $2.95 | $2.82 | 2,267,500 | |
| $2.88 | -0.11 | -3.7% | $3.02 | $3.03 | $2.79 | 2,113,100 | |
| $2.99 | +0.04 | +1.4% | $3.01 | $3.10 | $2.95 | 1,463,600 | |
| $2.95 | -0.19 | -6.1% | $3.19 | $3.33 | $2.93 | 3,384,900 | |
| $3.14 | -0.19 | -5.7% | $3.31 | $3.37 | $3.135 | 1,891,600 | |
| $3.33 | +0.20 | +6.4% | $3.16 | $3.37 | $3.13 | 2,609,200 | |
| $3.13 | +0.015 | +0.5% | $3.09 | $3.215 | $3.00 | 1,554,100 | |
| $3.115 | +0.135 | +4.5% | $3.015 | $3.16 | $2.98 | 2,776,000 | |
| $2.98 | -0.05 | -1.7% | $3.03 | $3.115 | $2.925 | 2,116,800 | |
| $3.03 | -0.05 | -1.6% | $3.03 | $3.06 | $2.88 | 2,807,600 | |
| $3.08 | -0.23 | -6.9% | $3.32 | $3.34 | $2.925 | 4,592,400 | |
| $3.31 | +0.01 | +0.3% | $3.33 | $3.42 | $3.285 | 1,357,800 | |
| $3.30 | -0.09 | -2.7% | $3.44 | $3.45 | $3.245 | 2,050,500 | |
| $3.39 | -0.025 | -0.7% | $3.43 | $3.475 | $3.38 | 1,630,900 | |
| $3.415 | -0.035 | -1.0% | $3.51 | $3.59 | $3.40 | 1,758,200 | |
| $3.45 | +0.02 | +0.6% | $3.44 | $3.53 | $3.425 | 2,320,800 | |
| $3.43 | 0.00 | 0.0% | $3.40 | $3.455 | $3.32 | 1,344,100 | |
| $3.43 | -0.08 | -2.3% | $3.46 | $3.54 | $3.41 | 1,485,400 | |
| $3.51 | +0.11 | +3.2% | $3.475 | $3.525 | $3.355 | 1,472,300 | |
| $3.40 | -0.04 | -1.2% | $3.40 | $3.41 | $3.31 | 1,167,600 | |
| $3.44 | -0.11 | -3.1% | $3.54 | $3.54 | $3.42 | 1,441,300 | |
| $3.55 | -0.21 | -5.6% | $3.72 | $3.735 | $3.55 | 2,172,400 | |
| $3.76 | +0.02 | +0.5% | $3.72 | $3.845 | $3.66 | 2,363,400 | |
| $3.74 | -0.05 | -1.3% | $3.83 | $3.85 | $3.70 | 2,227,700 | |
| $3.79 | -0.08 | -2.1% | $3.87 | $4.07 | $3.73 | 1,835,400 | |
| $3.87 | +0.16 | +4.3% | $3.68 | $3.935 | $3.66 | 2,364,100 | |
| $3.71 | -0.14 | -3.6% | $3.83 | $3.86 | $3.695 | 1,857,200 | |
| $3.85 | -0.25 | -6.1% | $4.07 | $4.10 | $3.83 | 1,824,700 | |
| $4.10 | -0.14 | -3.3% | $4.25 | $4.30 | $4.09 | 1,988,400 | |
| $4.24 | +0.04 | +1.0% | $4.17 | $4.24 | $4.03 | 1,861,700 | |
| $4.20 | +0.10 | +2.4% | $4.11 | $4.235 | $4.085 | 4,285,800 | |
| $4.10 | +0.10 | +2.5% | $3.97 | $4.14 | $3.81 | 1,752,900 | |
| $4.00 | -0.03 | -0.7% | $4.07 | $4.10 | $3.935 | 1,160,600 | |
| $4.03 | -0.18 | -4.3% | $4.14 | $4.15 | $3.832 | 2,272,700 |
- Ticker
- NASDAQ:CCCC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · Sep 25, 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 5, 2026
Closed $2.95 (-5.4%) on Nov 5, 2026
C4 Therapeutics to Participate in Upcoming November Investor Conferences
Nov 3, 2026
Closed $3.21 (0.0%) on Nov 3, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026
Closed $3.21 (0.0%) on Nov 3, 2026
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
Oct 29, 2026
Closed $3.30 (-2.8%) on Oct 29, 2026
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Sep 25, 2026
Closed $2.98 (-1.7%) on Sep 25, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed, Refractory Multiple Myeloma Trial
Sep 4, 2026
Closed $3.76 (+0.5%) on Sep 4, 2026
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Sep 3, 2026
Closed $3.74 (-1.3%) on Sep 3, 2026
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 11, 2026
Closed $3.87 (+6.9%) on Aug 11, 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Jun 11, 2026
Closed $3.87 (0.0%) on Jun 11, 2026
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
Closed $3.28 (+5.5%) on May 20, 2026
C4 Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 116 in all · newest Nov 5, 2026 · oldest 2020
- Decks
- 37 decks · latest Sep 25, 2026
Where C4 Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CCCC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CCCC | BOATS | United States | USD |
Valuation
EV/sales 5.4× against a median of 2,281×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $175.5M USD
- P/E
- Loss
- EV/sales
- 5.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.4×
- Gross margin
- 94.4%
- Operating margin
- −315.9%
- Net margin
- −282.2%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics, Inc. · NASDAQ:CCCC | US$325.7M | US$175.5M | n/a | 5.4× | n/a | 1.4× | −282.2% | 0.2× | 1.46 |
| Lyell Immunopharma, Inc. · NASDAQ:LYEL | US$339.3M | US$196.5M | n/a | 13,099× | n/a | 1.8× | n/a | 0.2× | 1.51 |
| Avacta Group PLC · LSE:AVCT | US$337.8M | US$337.2M | n/a | 2,281× | n/a | 68.5× | n/a | 5.3× | n/a |
| Inovio Pharmaceuticals, Inc. · NASDAQ:INO | US$329.7M | US$7.56B | n/a | 25,303× | 3.4× | n/a | n/a | n/a | 0.70 |
| Larimar Therapeutics, Inc. · NASDAQ:LRMR | US$328.6M | US$204.7M | n/a | n/a | n/a | 3.2× | n/a | 0.1× | 1.48 |
| CytoDyn Inc. · OTC:CYDY | US$326.4M | US$345.8M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Laekna, Inc. · HKEX:2105 | US$322.8M | US$154.7M | n/a | 9.7× | n/a | 1.8× | −214.9% | 0.0× | n/a |
| Foresee Pharmaceuticals Co., Ltd. · TPEX:6576 | US$319.8M | US$303.4M | 469× | 21.2× | n/a | 8.3× | 4.8% | 0.3× | n/a |
| GI Innovation, Inc. · KRX:358570 | US$317.8M | US$288.6M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Atea Pharmaceuticals, Inc. · NASDAQ:AVIR | US$317.6M | US$126.6M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 0.86 |
| MapLight Therapeutics, Inc. · NASDAQ:MPLT | US$313.9M | US$29.84M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.28 |
| Median of the others | US$324.6M | US$246.6M | 469× | 2,281× | 3.4× | 2.5× | −105.1% | 0.0× | 1.07 |
Forecasts
7 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.75 · 6 analysts
- Revenue, year to Dec 2026
- 26.85M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Andrew Hirsch | President and Chief Executive Officer, Director |
| Courtney SolbergAssociate | Director, Investor Relations |
| Leah Gibson | Vice President, Investor Relations & Communications |
| Marc Cohen | In MemoriamCo-Founder & Executive Chairman Emeritus |
Board
| Director | Role |
|---|---|
| Marc Cohen | In MemoriamCo-Founder & Executive Chairman Emeritus |
| Ron Cooper | Chairman |
| Andrew Hirsch | President and Chief Executive Officer, Director |
| Donna Grogan | Director |
| Ken Anderson | Director |
| Laura Bessen | Director |
| Owen Hughes | Director |
| Stephen Fawell | Director |
| Steve Hoerter | Director |
| Utpal Koppikar | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −5.5% |
| Q2 2026 | Aug 11, 2026 · Before open | +6.9% |
| Q1 2026 | May 12, 2026 · Before open | 0.0% |
| Q4 2025 | Feb 26, 2026 | −2.5% |
| Q3 2025 | Nov 6, 2025 · Before open | +0.4% |
| Q2 2025 | Aug 7, 2025 · Before open | +31.6% |
| Q1 2025 | May 7, 2025 · Before open | +6.4% |
| Q4 2024 | Feb 20, 2025 · Before open | −0.7% |
| Q3 2024 | Oct 31, 2024 · Before open | −3.6% |
| Q2 2024 | Aug 1, 2024 · Before open | −0.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −5.0% |
| Q4 2023 | Feb 22, 2024 · Before open | +21.4% |
| Q3 2023 | Nov 1, 2023 · Before open | −11.4% |
| Q2 2023 | Aug 8, 2023 · Before open | −0.3% |
| Q1 2023 | May 4, 2023 · Before open | +2.9% |
| Q4 2022 | Feb 23, 2023 · Before open | +1.7% |
| Q3 2022 | Nov 3, 2022 · Before open | +2.1% |
| Q2 2022 | Aug 4, 2022 · Before open | +7.0% |
| Q1 2022 | May 5, 2022 · Before open | −4.0% |
| Q4 2021 | Feb 24, 2022 · Before open | +14.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 25 slides | Sep 25, 2026 |
| Investor Presentation (June 2026) | Investor deck | 26 slides | Jun 11, 2026 |
| Investor Presentation (May 2026) | Investor deck | 23 slides | May 12, 2026 |
| Investor Presentation (April 2026) | Investor deck | 26 slides | Apr 9, 2026 |
| Investor Presentation (October 2025) | Investor deck | 33 slides | Oct 16, 2025 |
| International Myeloma Society (IMS) Annual Meeting 2025 | Conference | 39 slides | Sep 22, 2025 |
| Corporate Update (August 2025) | Corporate update | 23 slides | Aug 7, 2025 |
| Investor Presentation (May 2025) | Investor deck | 26 slides | May 2025 |
| Investor Presentation (January 2025) | Investor deck | 37 slides | Jan 14, 2025 |
| Investor Presentation (December 2024) | Investor deck | 37 slides | Dec 9, 2024 |
All 37 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants, each with a Class A Warrant and a Class B Warrant Announced: US$125M–US$349.7M · US$2.47 a share · Warrants at US$2.22 · Jefferies +2 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead) Buyers: RA Capital Management (led the offering); OrbiMed; Soleus Capital; Lynx1 Capital Management; Bain Capital Life Sciences Use of proceeds: Fund ongoing and planned clinical trials of cemsidomide, other R&D, working capital and general corporate purposes | Oct 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Oct 1, 2020.
- Price
- US$19.00 a share
- Shares offered
- 9,600,000 shares of common stock
- Offering size
- US$182.4 million
- Underwriters' option
- Up to 1,440,000 more shares
- Underwriters
- Jefferies, Evercore ISI, BMO Capital Markets, UBS Investment Bank · In the order on the cover
- Shares delivered
- On or about Oct 6, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 6, 2020 |
| Filed publicly | Sep 10, 2020 |
| Amended once | Sep 28, 2020 |
| Shares registered with an exchange | Sep 28, 2020 |
| Declared effective by the SEC | Oct 1, 2020 |
| Final prospectus, with the price | Oct 2, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 2, 2020 |
| EFFECT · Notice that a registration is effective | Oct 1, 2020 |
| S-1MEF · Registration of more shares for the same offering | Oct 1, 2020 |
| CERT · Exchange's certificate of listing | Oct 1, 2020 |
| CORRESP · Letter to the SEC | Sep 29, 2020 |
| CORRESP · Letter to the SEC | Sep 29, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 28, 2020 |
| S-1/A · Registration statement, amended | Sep 28, 2020 |
| CORRESP · Letter to the SEC | Sep 15, 2020 |
| CORRESP · Letter to the SEC | Sep 10, 2020 |
All 13 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Sep 10, 2020 |
| UPLOAD · Letter from the SEC | Sep 2, 2020 |
| DRS · Draft registration statement | Aug 6, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 2, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 35.9M | 35.6M | 20.8M | 31.1M | 45.8M | 33.2M | 21.4M | 19.4M |
| Cost of revenue | 7.97M | 7.89M | 7.74M | 7.57M | 2.91M | 78.4M | 47.7M | 28.6M |
| Gross profit | 28.0M | 35.6M | 13.0M | 31.1M | 45.8M | -45.2M | 21.4M | -9.23M |
| Research and development | 104.2M | 110.6M | 117.7M | 117.8M | 94.7M | 78.4M | 48.1M | 28.6M |
| Selling, general and administrative | 36.2M | 42.1M | 42.1M | 42.8M | 33.3M | 15.2M | 8.77M | 7.16M |
| Operating income | -115.2M | -119.6M | -139.0M | -129.5M | -82.1M | -60.4M | -35.5M | -16.4M |
| Depreciation and amortization | 1.96M | 1.82M | 1.88M | 1.68M | 1.49M | 1.62M | 1.59M | 1.27M |
| EBITDA | -113.3M | -117.8M | -137.2M | -127.9M | -80.6M | -58.8M | -33.9M | -15.1M |
| Interest expense | 0 | 1.37M | 2.22M | 2.15M | 1.23M | 2.16M | 0 | |
| Income before tax | -104.9M | -105.2M | -131.2M | -128.2M | -83.9M | -67.0M | -33.3M | -15.7M |
| Income tax | 121.0K | 131.0K | 1.28M | 0 | 0 | -626.0K | 804.0K | 678.0K |
| Net income | -105.0M | -105.3M | -132.5M | -128.2M | -83.9M | -66.3M | -34.1M | -15.7M |
| Earnings per share, basic | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 | -0.37 |
| Earnings per share, diluted | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 74.6M | 55.5M | 126.6M | 29.8M | 76.1M | 181.7M | 90.5M | 36.3M |
| Short-term investments | 173.9M | 189.4M | 127.1M | 246.4M | 233.2M | 190.0M | ||
| Receivables | 2.40M | 3.10M | 11.8M | 1.47M | 5.72M | 4.48M | 4.62M | 86.4M |
| Inventory | -61.0M | 1 | 1 | |||||
| Current assets | 258.1M | 257.8M | 271.2M | 287.6M | 325.7M | 381.0M | 96.8M | 123.5M |
| Property, plant and equipment | 4.74M | 5.84M | 7.13M | 7.40M | 3.11M | 3.32M | 4.46M | 20.4M |
| Total assets | 359.1M | 349.6M | 376.5M | 430.8M | 506.8M | 400.1M | 118.3M | 146.5M |
| Accounts payable | 858.0K | 1.33M | 1.45M | 1.17M | 4.51M | 5.68M | 5.38M | 1.15M |
| Current liabilities | 33.0M | 45.2M | 42.8M | 44.5M | 51.2M | 43.9M | 33.6M | 23.9M |
| Long-term debt | 0 | 9.20M | 10.8M | 10.1M | ||||
| Total debt | 60.0M | 65.8M | 0 | 11.5M | 10.8M | 10.1M | 13.7M | 14.5M |
| Total liabilities | 102.5M | 133.6M | 130.3M | 141.6M | 117.2M | 119.3M | 119.2M | 226.2M |
| Shareholders' equity | 256.6M | 216.0M | 246.1M | 289.2M | 389.6M | 280.8M | -112.0M | -79.8M |
| Shares outstanding | 96.9M | 70.6M | 60.5M | 49.0M | 48.7M | 43.1M | 1.43M | 42.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -98.7M | -65.2M | -106.8M | -105.9M | -87.0M | -67.2M | 55.6M | -17.0M |
| Capital spending | -607.0K | -180.0K | -1.71M | -5.50M | -1.28M | -650.0K | -1.35M | -2.69M |
| Free cash flow | -99.3M | -65.3M | -108.5M | -111.4M | -88.2M | -67.9M | 54.3M | -19.7M |
| Cash from investing | -8.60M | -51.3M | 158.3M | 58.4M | -189.3M | -190.5M | -1.62M | 36.9M |
| Cash from financing | 126.4M | 45.3M | 45.5M | 1.15M | 171.4M | 348.9M | 244.0K | 1.96M |
| Dividends paid | -12.0M | |||||||
| Share buybacks | -193.0K | -194.0K | -110.0K | 0 | 2.04M | -194.0K | -30.0K | -63.0K |
| Change in cash | 19.1M | -71.1M | 97.0M | -46.4M | -104.9M | 91.2M | 54.2M | 21.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 19, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 10, 2026 | Current report | SEC |
| 8-K · Current report | Apr 9, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 11, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Dec 10, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 16, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 16, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 15, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Nov 15, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 14, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 14, 2024 | Other filings | SEC |
| SUPPL | Nov 13, 2024 | Other filings | SEC |
| SUPPL | Nov 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Nov 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 8, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Nov 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 7, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 31, 2024 | Offer document | SEC |
| S-3 · Registration statement | Oct 31, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 31, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 29, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 8-K/A · Current report, amended | Oct 15, 2024 | Management or board change | SEC |
| 8-K · Current report | Oct 15, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Oct 11, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 11, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
This page holds 200 of 552 filings. Open Filings
Cap table
Built by 6ix from C4 Therapeutics, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 131,317,488
- Fully diluted
- 131,317,488
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 131,317,488 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 131,317,488 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Owen Hughes Other companies: AnaptysBio, Inc. (Member of the Audit Committee · Since at least May 11, 2026); XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Cullinan Therapeutics, Inc. (President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past) | Director · Since at least Nov 16, 2023 |
| William McKee Other companies: Assertio Holdings, Inc. (Director · Since at least May 19, 2020); Rein Therapeutics, Inc. (Director · Jun 19, 2019 – Jun 15, 2022 · Past); Depomed Inc (Director · Mar 28, 2017 – May 8, 2018 · Past); Dare Bioscience, Inc. (Director · Apr 10, 2014 – Jan 3, 2017 · Past); Auxilium Pharmaceuticals Inc (Director · Mar 18, 2009 – Jan 29, 2015 · Past); Barr Pharmaceuticals Inc (EVP, CFO · Jan 3, 2006 – Dec 23, 2008 · Past) | Chief Financial Officer · Oct 1, 2020 – Oct 6, 2020 · Past |
| Bruce Downey Other companies: Melinta Therapeutics Inc (Director · Oct 31, 2018 – Jun 11, 2019 · Past); Cardinal Health, Inc. (Director · Aug 31, 2009 – Jun 30, 2023 · Past); Momenta Pharmaceuticals Inc (Director · Jun 11, 2009 – Oct 1, 2020 · Past); Barr Pharmaceuticals Inc (Chairman & CEO, Director · Jul 26, 2006 – Dec 23, 2008 · Past) | Director · Oct 1, 2020 – Jun 20, 2024 · Past |
| Andrew Hirsch Other companies: Editas Medicine, Inc. (Board Member · Since at least May 30, 2017); Agios Pharmaceuticals, Inc. (Chief Financial Officer · Sep 19, 2016 – Apr 22, 2020 · Past); BIND Therapeutics Inc (PRESIDENT & CEO, Director · Sep 19, 2013 – Jun 22, 2015 · Past) | President and Chief Executive Officer, Director · Since at least Oct 1, 2020 |
| Utpal Koppikar Other companies: Insmed Incorporated (Director · Since at least Oct 19, 2026); Flexion Therapeutics Inc (Director · Jul 9, 2021 – Nov 19, 2021 · Past); Atara Biotherapeutics, Inc. (Chief Financial Officer · Jun 7, 2018 – Mar 2, 2023 · Past) | Director · Since at least Mar 16, 2022 |
| Adam Crystal Other companies: Tango Therapeutics, Inc. (President, Research & Development · Since at least Feb 27, 2023) | Chief Medical Officer · May 25, 2022 – Jan 30, 2023 · Past |
| Donna Grogan Other companies: Momenta Pharmaceuticals Inc (Director · Sep 18, 2019 – Oct 1, 2020 · Past) | Director · Since at least Jul 29, 2022 |
| Jolie Siegel Other companies: Odyssey Therapeutics, Inc. (See Remarks · Since at least May 7, 2026) | Chief Legal Officer · Oct 1, 2020 – Feb 13, 2025 · Past |
| Marc Cohen Other companies: Korro Bio, Inc. (Director · Oct 2, 2019 – Jun 21, 2022 · Past) | In MemoriamCo-Founder & Executive Chairman Emeritus · Since at least Oct 1, 2020 |
| Alain J Cohen | Director · Oct 1, 2020 – Apr 4, 2022 · Past |
All 22 people
| Person | Seat |
|---|---|
| Courtney SolbergAssociate | Director, Investor Relations · Since at least Nov 3, 2026 |
| Ken Anderson | Director · Since at least Oct 2, 2026 |
| Kendra Adams | Chief Financial Officer · Since at least Sep 18, 2023 |
| Kenneth Carl Anderson | Director · Since at least Oct 1, 2020 |
| Laura Bessen | Director · Since at least Jun 18, 2025 |
| Laura Jean Wahlberg | VP of Finance Corp Controller · Oct 1, 2020 – Feb 11, 2021 · Past |
| Leah Gibson | Vice President, Investor Relations & Communications · Since at least May 20, 2026 |
| Leonard Reyno | Chief Medical Officer · Since at least Jul 10, 2023 |
| Ron Cooper | Chairman · Since at least Nov 4, 2026 |
| Scott N Boyle | Chief Business Officer · Since at least Feb 13, 2026 |
| Stephen Fawell | Director · Since at least Aug 29, 2024 |
| Steve Hoerter | Director · Since at least Nov 20, 2024 |
Log in to ask 6ix AI your own questions about C4 Therapeutics, Inc.